Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Retzer

Interventional Cardiology McHenry, IL Medical Doctor

NPI 1639331655 CMS profile 580521

4309 W Medical Center Dr Ste A200, Ste A200, McHenry, IL 60050

Open in the dashboard

General payments

$8,255

123 records reported · program years 2019–2025

Research payments

$2,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Retzer of McHenry, IL is reported in the CMS Open Payments database as having received $8,255 across 123 general payments and $2,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,671 43
2024 General $863 25
2023 General $2,058 23
2023 Research $2,000 1
2022 General $193 6
2021 General $198 7
2020 General $99 4
2019 General $2,172 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Retzer
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Elizabeth Retzer were reported at $2,671. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Elizabeth Retzer Interventional Cardiology median Middle half National median
2019 $2,172 $1,097 $329–$3,048 $163
2020 $99 $473 $161–$1,480 $114
2021 $198 $677 $233–$1,827 $132
2022 $193 $978 $333–$2,724 $149
2023 $2,058 $1,136 $382–$2,986 $160
2024 $863 $1,181 $395–$3,326 $164
2025 $2,671 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,420 54 payments
  2. Abbott Laboratories $1,749 18 payments
  3. Abiomed $840 7 payments
  4. Edwards Lifesciences Corporation $384 13 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $311 9 payments
  6. Stryker Corporation $149 8 payments
  7. Medtronic Vascular, Inc. $89 1 payment
  8. Bolton Medical Inc $56 1 payment
  9. Boston Scientific Corporation $53 2 payments
  10. W. L. Gore & Associates, Inc. $47 2 payments
  11. Other $157 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,338 104 payments
  2. Travel and Lodging $3,827 18 payments
  3. Grant $89 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $4,401 53 payments
  2. Xience V coronary stent system $1,275 5 payments
  3. Impella $692 6 payments
  4. LifeVest $311 9 payments
  5. SAPIEN 3 Ultra RESILIA $177 5 payments
  6. Xience Sierra Coronary Stent System $164 3 payments
  7. NAVITOR $150 2 payments
  8. CoreValve Evolut $89 1 payment
  9. RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM $56 1 payment
  10. ARTIX MT $52 3 payments
  11. Other $545 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $2,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

4,931

Median for Cardiology: 2,533

Drug cost

$559,637

Median for Cardiology: $485,213

Branded share of claims

21.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 227 $314,305
Jardiance Empagliflozin Brand 35 $40,926
Xarelto Rivaroxaban Brand 26 $38,922
Repatha Sureclick Evolocumab Brand 40 $38,468
Entresto Sacubitril/Valsartan Brand 34 $36,253
Brilinta Ticagrelor Brand 18 $16,463
Ezetimibe Generic 177 $8,258
Atorvastatin Calcium Generic 717 $7,683
Metoprolol Succinate Generic 453 $7,368
Bumetanide Generic 86 $3,580

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$304,680

Medicare's payments for the services billed

Medicare patients

4,198

Average age 76

Services billed

8,828

2,266 women, 1,932 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
Arthritis 54%
Heart failure 40%
Atrial fibrillation 37%
Diabetes 36%
Chronic kidney disease 36%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record